Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 6/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | PDE1A | P54750 | 9/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 9/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 9/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729785 | 0.84 | CHRM1 (0.51) | NPBWR1MCHR1PDE1APDE1BPDE1C | |
| SCHEMBL27393064 | 0.72 | CMA1 (0.50) | NPBWR1MCHR1MAPTTP53LMNA | |
| SCHEMBL22729794 | 0.72 | MAPT (0.45) | MCHR1MAPTTP53LMNAKDM4E | |
| SCHEMBL22729427 | 0.72 | KCNH2 (0.44) | MCHR1MAPTTP53LMNAKDM4E | |
| SCHEMBL22729465 | 0.71 | MAPT (0.51) | MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL4678834 | 0.71 | MEN1 (0.46) | MAPTTP53LMNAKDM4EALDH1A1 | |
| SCHEMBL23535857 | 0.70 | NPBWR1 (0.67) | NPBWR1MCHR1 | |
| SCHEMBL2400441 | 0.70 | CYP11B2 (0.56) | NPBWR1MCHR1MAPTTP53LMNA | |
| SCHEMBL1311870 | 0.70 | NPBWR1 (0.63) | NPBWR1MCHR1PDE1APDE1BPDE1C | |
| SCHEMBL21553152 | 0.70 | CMA1 (0.47) | NPBWR1PDE1BMAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | NPBWR1 1916/4885MCHR1 2356/4885PDE1A 653/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | NPBWR1 1953/4885MCHR1 2232/4885PDE1A 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.